Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00321815 · ClinicalTrials.gov registry record · Phase 2
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00321815 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 43 participants.
The verdict
NCT00321815, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Interventions
- DRUG Erlotinib
- DRUG PF-3512676 + Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2006-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00321815
The ClinicalTrials.gov registry entry for NCT00321815 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00321815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00321815 about?
NCT00321815 is a clinical study titled "Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer". To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
What is the current status of trial NCT00321815?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2006-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00321815?
The interventions under investigation include: Erlotinib (DRUG), PF-3512676 + Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00321815?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.